7/10, 3:00 PM (Source: TeleTrader)
more TeleTrader news

Gilead: Remdesivir reduces risk of death in COVID-19 patients

The antiviral drug remdesivir developed by Gilead Sciences could reduce the risk of death among coronavirus patients by 62%, according to new data released by the company on Friday.

"In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care - an important finding that requires confirmation in prospective clinical trials," Gilead said in a press release.

Remdesivir was first developed as a treatment for the Ebola virus. Earlier this month, it became the first COVID-19 treatment approved by the European Commission, while Australia followed suit today as its Therapeutic Goods Administration said it is granting it provisional approval for treating corona virus patients.

Breaking the News / JC